BioLineRx (BLRX) Non-Current Debt (2015 - 2025)

BioLineRx's Non-Current Debt history runs 11 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• In Q4 2025, Non-Current Debt fell 50.21% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $4.5 million (down 50.21% YoY), while the FY2025 annual figure was $4.5 million, down 50.21% from the prior year.
• Non-Current Debt was $4.5 million for Q4 2025 at BioLineRx, down from $5.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $18.8 million in Q2 2024 to a low of $1.0 million in Q2 2021.
• Historically, Non-Current Debt has averaged $8.0 million across 5 years, with a median of $7.9 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Non-Current Debt slumped 76.76% in 2021, then soared 121.19% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $1.0 million in 2021, then surged by 757.46% to $8.6 million in 2022, then decreased by 23.16% to $6.6 million in 2023, then jumped by 35.15% to $9.0 million in 2024, then plunged by 50.21% to $4.5 million in 2025.
• The last three Non-Current Debt figures came in at $4.5 million (Q4 2025), $5.6 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.